On May 21, 2021 Imago BioSciences, Inc. ("Imago"), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), reported that updated Phase 2 data from its two clinical programs for bomedemstat (IMG-7289) will be highlighted in e-poster presentations at the European Hematology Association (EHA) (Free EHA Whitepaper) 2021 Virtual Congress, held online June 9 – 17, 2021 (Press release, Imago BioSciences, MAY 21, 2021, View Source [SID1234580458]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2021 EHA (Free EHA Whitepaper) Virtual Congress Presentation Information

Title: A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for the Treatment of Essential Thrombocythemia
Session Title: Myeloproliferative neoplasms – Clinical
Abstract: EHA (Free EHA Whitepaper)-2504

Title: A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for the Treatment of Advanced Myelofibrosis
Session Title: Myeloproliferative neoplasms – Clinical
Abstract: EHA (Free EHA Whitepaper)-2787

The abstracts are available on the EHA (Free EHA Whitepaper) Annual Congress website at www.ehaweb.org/congress. All e-poster presentations will be made available on the EHA (Free EHA Whitepaper) website for on-demand viewing on June 11, 2021.